Alivus Life Sciences Declares Unaudited Q1 FY27 Results

Alivus Life Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved the results during a meeting held on July 30, 2026. The company's results were subjected to a limited review by the statutory auditors. The company operates in a single reporting segment: Active Pharmaceutical Ingredient (API). During the quarter, the company allotted 3,100 equity shares under its Employee Stock Option Scheme, increasing its paid-up equity share capital.